CRNA Stock Overview
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.85 |
| 52 Week High | kr23.97 |
| 52 Week Low | kr2.41 |
| Beta | 1.98 |
| 1 Month Change | -57.36% |
| 3 Month Change | -58.87% |
| 1 Year Change | -84.92% |
| 3 Year Change | -98.74% |
| 5 Year Change | -98.53% |
| Change since IPO | -99.61% |
Recent News & Updates
Recent updates
Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price
Aug 24
Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?
Jul 08Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Oct 27Is Targovax (OB:TRVX) A Risky Investment?
Jul 05Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now
Mar 10Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Feb 20The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares
Dec 05
Shareholder Returns
| CRNA | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -48.0% | -3.8% | -0.6% |
| 1Y | -84.9% | -75.2% | 2.8% |
Return vs Industry: CRNA underperformed the Norwegian Biotechs industry which returned -72.2% over the past year.
Return vs Market: CRNA underperformed the Norwegian Market which returned 3.2% over the past year.
Price Volatility
| CRNA volatility | |
|---|---|
| CRNA Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: CRNA's share price has been volatile over the past 3 months.
Volatility Over Time: CRNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 17 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
| CRNA fundamental statistics | |
|---|---|
| Market cap | kr21.70m |
| Earnings (TTM) | -kr449.26m |
| Revenue (TTM) | kr10.00m |
2.2x
P/S Ratio0.0x
P/E RatioIs CRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNA income statement (TTM) | |
|---|---|
| Revenue | kr10.00m |
| Cost of Revenue | kr0 |
| Gross Profit | kr10.00m |
| Other Expenses | kr459.26m |
| Earnings | -kr449.26m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -59.00 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,491.69% |
| Debt/Equity Ratio | -135.9% |
How did CRNA perform over the long term?
See historical performance and comparison